United States v. Sardesai

CourtCourt of Appeals for the Fourth Circuit
DecidedOctober 10, 1997
Docket96-4228
StatusUnpublished

This text of United States v. Sardesai (United States v. Sardesai) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Sardesai, (4th Cir. 1997).

Opinion

UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

UNITED STATES OF AMERICA, Plaintiff-Appellant,

v. No. 96-4228 SUHAS V. SARDESAI; EDMUND J. STRIEFSKY, Defendants-Appellees.

Appeal from the United States District Court for the District of Maryland, at Greenbelt. Peter J. Messitte, District Judge. (CR-94-167-PJM)

Argued: November 1, 1996

Decided: October 10, 1997

Before ERVIN, Circuit Judge, BOYLE, United States District Judge for the Eastern District of North Carolina, sitting by designation, and JACKSON, United States District Judge for the Eastern District of Virginia, sitting by designation.

_________________________________________________________________

Affirmed by unpublished opinion. Judge Ervin wrote the opinion, in which Judge Boyle and Judge Jackson joined.

_________________________________________________________________

COUNSEL

ARGUED: Lawrence McDade, Deputy Director, Office of Consumer Litigation, UNITED STATES DEPARTMENT OF JUSTICE, Wash- ington, D.C., for Appellant. L. Marc Durant, DURANT & DURANT, Philadelphia, Pennsylvania; Catherine N. Recker, WELSH & RECKER, Philadelphia, Pennsylvania, for Appellees. ON BRIEF: Lynne A. Battaglia, United States Attorney, Raymond A. Bonner, Assistant United States Attorney, Greenbelt, Maryland, for Appellant. Robert E. Welsh, Jr., WELSH & RECKER, Philadelphia, Pennsylva- nia, for Appellee Sardesai.

_________________________________________________________________

Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).

_________________________________________________________________

OPINION

ERVIN, Circuit Judge:

Suhas Sardesai and Edmund Striefsky were both convicted of con- spiracy to defraud the United States Food and Drug Administration, in violation of 18 U.S.C. § 371; two counts of introduction of adulter- ated pharmaceuticals into interstate commerce in violation of 21 U.S.C. §§ 331(a) and 333(a)(2); and several counts of making false statements to a federal agency in violation of 18 U.S.C. § 1001. Appellants moved for new trials under Federal Rule of Criminal Pro- cedure 33 on the basis of United States v. Gaudin, 115 S. Ct. 2310 (1995), which was decided shortly after Sardesai and Striefsky were convicted. The district court read Gaudin to mean that it had erred in the instant case when it failed to allow the jury to decide materiality, an essential element of the false statement charges. The district court further found that the instructional error had infected the verdicts on all of the charges and it vacated the convictions and granted a new trial for Sardesai and Striefsky. The government appeals the grant of the new trials. For the reasons explored below, we affirm.

I

During the relevant years, Sardesai and Striefsky were executives at Mutual Pharmaceutical Company, and both had been there since

2 the mid-1980s. Beginning in 1987 Mutual began to experience diffi- culty in manufacturing several drug products according to the meth- ods that had been approved by the Food and Drug Administration ("FDA").1 Under the direction of Sardesai and Striefsky, Mutual failed to follow the supplemental approval process established by the FDA for changes to drug formulae and manufacturing methods. Instead Mutual began to make some drug products using unapproved ingredients and processes, mixed batches of failed products with suc- cessful ones, and remilled and remixed flawed tablets. Many Mutual employees testified at trial about making these and other changes pur- suant to the instruction of Sardesai and Striefsky. Testimony also showed that employees were often told to sign records documenting work they had not done and not to document the work they had done in violation of FDA procedures. Mutual submitted false documents to the FDA indicating that "no significant changes" had been made in the approved manufacturing process. Following the manufacturing changes and the false documentation, Mutual introduced the altered drugs into interstate commerce and allowed them to be sold to con- sumers. At least six different drugs were affected by Mutual's illegal practices.

II

The government first argues that the false statement counts them- selves need not be retried in light of Gaudin . We note from the outset that we review the district court's decision to grant a new trial pursu- ant to Rule 33 for an abuse of discretion. See United States v. Campbell, 977 F.2d 854, 860 (4th Cir. 1992); see also United States v. Christy, 3 F.3d 765, 768 (4th Cir. 1993) (employing abuse of dis- cretion standard for review of denial of a motion for a new trial based upon newly discovered evidence); United States v. Arrington, 757 F.2d 1484, 1486 (4th Cir. 1995) (same); United States v. McBride, 862 F.2d 1316, 1319 (8th Cir. 1988) (applying abuse of discretion _________________________________________________________________ 1 Federal law requires that a drug manufacturer submit detailed data to the F.D.A. regarding the exact process which will be used in making and testing a drug product. 21 U.S.C. § 355. Drugs not made in accordance with approved processes or drugs for which inaccurate records are kept regarding manufacturing and testing are "adulterated," and cannot be sold. 21 U.S.C. § 351(a)(2)(B); 21 C.F.R. part 211.

3 standard to district court's decision to grant a new trial in light of trial errors.)

A

In Gaudin, the Supreme Court held that when materiality is an essential element of a crime, it must be decided by the jury and not reserved as a question of law to be decided by the judge. 115 S. Ct. 2310 (1995). Both Gaudin and the instant case concern violations of 18 U.S.C. § 1001, which criminalizes the making of false statements to an agency of the United States.2 Based upon Gaudin, the district court in the instant case found that it erroneously prevented the jury from deciding whether the false statements made by Sardesai and Striefsky were material in violation of § 1001, and granted a new trial.

The government argues that Gaudin does not apply to this case. Specifically the government points out that materiality is not an explicit element of violation of all portions of§ 1001, but is only mentioned in the first clause of § 1001;3 the government implies that Sardesai and Striefsky were charged with violating a portion of § 1001 which does not include materiality as an element.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Toussaint
84 F.3d 1406 (Eleventh Circuit, 1996)
Pinkerton v. United States
328 U.S. 640 (Supreme Court, 1946)
United States v. Olano
507 U.S. 725 (Supreme Court, 1993)
United States v. Gaudin
515 U.S. 506 (Supreme Court, 1995)
Johnson v. United States
520 U.S. 461 (Supreme Court, 1997)
United States v. James E. Arrington
757 F.2d 1484 (Fourth Circuit, 1985)
United States v. Gene McBride
862 F.2d 1316 (Eighth Circuit, 1988)
United States v. William Ronald Forbes
64 F.3d 928 (Fourth Circuit, 1995)
United States v. William Calvin Johnson
71 F.3d 139 (Fourth Circuit, 1995)
United States v. Roger J. Raether Russell Hawkins
82 F.3d 192 (Eighth Circuit, 1996)
United States v. Karl v. David
83 F.3d 638 (Fourth Circuit, 1996)
United States v. Wells
519 U.S. 482 (Supreme Court, 1997)
United States v. Jerke
896 F. Supp. 962 (D. South Dakota, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Sardesai, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-sardesai-ca4-1997.